Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00963131 | High-dose Antioxidants for Central Serous Chorioretinopathy | PHASE2 | COMPLETED | 60 | — | — | Dec 1, 2004 | Jun 1, 2009 | Dec 30, 2009 | 1 | Thailand |
| Arm | Type | Description |
|---|---|---|
| antioxidant tablets | EXPERIMENTAL | the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease |
| placebo tablets | PLACEBO_COMPARATOR | the control arm received placebo tablets for 3 months or until the resolution of the disease |
| Name | Type | Description |
|---|---|---|
| antioxidants tablets | DRUG | vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms. |
Inclusion Criteria: 1. patients with acute central serous chorioretinopathy within 6 weeks of onset 2. age between 30-50 years 3. new or recurrent attack (the symptom-free period should longer than 6 months) 4. fluorescein angiography (FA) confirmed the diagnosis with the inkblot or smoke-stack lea...